TransCode Therapeutics, Inc.
RNAZ
$7.21
-$0.355-4.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.38M | 5.95M | 5.23M | 6.26M | 6.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.54M | 15.66M | 14.67M | 17.81M | 17.82M |
| Operating Income | -15.54M | -15.66M | -14.67M | -17.81M | -17.82M |
| Income Before Tax | -25.51M | -16.76M | -14.93M | -17.91M | -17.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.51 | -16.76 | -14.93 | -17.91 | -17.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.51M | -16.76M | -14.93M | -17.91M | -17.06M |
| EBIT | -15.54M | -15.66M | -14.67M | -17.81M | -17.82M |
| EBITDA | -15.47M | -15.57M | -14.55M | -17.68M | -17.69M |
| EPS Basic | -487.79 | -417.64 | -146.06 | -- | -- |
| Normalized Basic EPS | -304.89 | -261.04 | -91.29 | -- | -- |
| EPS Diluted | -487.79 | -417.64 | -146.06 | -- | -- |
| Normalized Diluted EPS | -304.89 | -261.04 | -91.29 | -- | -- |
| Average Basic Shares Outstanding | 210.00K | 37.70K | 15.90K | -- | -- |
| Average Diluted Shares Outstanding | 210.00K | 37.70K | 15.90K | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |